Your browser doesn't support javascript.
loading
Screening for late-onset Pompe disease in Poland.
Jastrzebska, Aleksandra; Potulska-Chromik, Anna; Lusakowska, Anna; Jastrzebski, Milosz; Lipowska, Marta; Kierdaszuk, Biruta; Kaminska, Anna; Kostera-Pruszczyk, Anna.
Afiliação
  • Jastrzebska A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
  • Potulska-Chromik A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
  • Lusakowska A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
  • Jastrzebski M; Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland.
  • Lipowska M; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
  • Kierdaszuk B; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
  • Kaminska A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
  • Kostera-Pruszczyk A; Department of Neurology, Medical University of Warsaw, Warsaw, Poland.
Acta Neurol Scand ; 140(4): 239-243, 2019 Oct.
Article em En | MEDLINE | ID: mdl-31125121
ABSTRACT

OBJECTIVES:

We aimed to screen for late-onset Pompe disease using the dried blood spot (DBS) test in a cohort of patients with limb-girdle muscle weakness or persistent hyperCKemia. MATERIALS AND

METHODS:

Patients with limb-girdle muscle weakness, persistently elevated CK, rigid spine syndrome, dyspnoea, myalgia or sibling of the patient diagnosed with LOPD were included in the study. Acid α-glucosidase (GAA) activity was measured on DBS by tandem mass spectrometry and followed by genetic testing when required. Study was conducted between June 2014 and May 2017.

RESULTS:

A total of 337 patients aged 32.2 years (range 2-80) were included in the study. Late-onset Pompe disease was diagnosed in 10 patients (3.0% of tested cohort). All were compound heterozygotes with common c.32-13T>G mutation on one allele and missense or frameshift mutation on the other. Two of the mutations (c.1951delG and c.397T>G) were not reported previously. Seven of the patients started enzyme replacement therapy.

CONCLUSIONS:

DBS test is a reliable method for screening for late-onset Pompe disease.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Depósito de Glicogênio Tipo II / Testes Genéticos Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Depósito de Glicogênio Tipo II / Testes Genéticos Tipo de estudo: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article